Comparative Pharmacology
Head-to-head clinical analysis: BUTAPAP versus ESGIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUTAPAP versus ESGIC.
BUTAPAP vs ESGIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Butapap is a combination analgesic containing butalbital (barbiturate) and acetaminophen. Butalbital potentiates the analgesic effect of acetaminophen by increasing GABAergic inhibition in the central nervous system, while acetaminophen inhibits cyclooxygenase (COX) enzymes in the brain, reducing prostaglandin synthesis.
Esgic contains butalbital (a barbiturate that enhances GABA-A receptor activity, producing sedation), acetaminophen (inhibits cyclooxygenase, particularly COX-2, in the CNS, reducing pain and fever), and caffeine (antagonizes adenosine receptors, providing vasoconstriction and adjuvant analgesic effect).
Butalbital/acetaminophen/caffeine: 1-2 capsules (50 mg butalbital/325 mg acetaminophen/40 mg caffeine) orally every 4 hours as needed, not to exceed 6 capsules per day.
1-2 capsules (50 mg butalbital, 325 mg acetaminophen, 40 mg caffeine) orally every 4 hours as needed, not to exceed 6 capsules per day.
None Documented
None Documented
Terminal elimination half-life: 2–3 hours; prolongation may occur in hepatic impairment.
Butalbital: ~35 hours; acetaminophen: ~2-3 hours; caffeine: ~3-6 hours. Clinical context: butalbital's long half-life leads to accumulation with repeated dosing, requiring cautious use.
Renal excretion of unchanged drug and metabolites (primarily glucuronide conjugates): ~90%; biliary/fecal excretion: ~10%.
Renal: butalbital 60-70% unchanged, acetaminophen ~4% unchanged, caffeine ~1% unchanged. Biliary/fecal: minimal.
Category C
Category C
Barbiturate Combination
Barbiturate Combination